Search

Your search keyword '"Thaker, Premal H"' showing total 87 results

Search Constraints

Start Over You searched for: "Thaker, Premal H" Remove constraint "Thaker, Premal H" Publisher elsevier bv Remove constraint Publisher: elsevier bv
87 results on '"Thaker, Premal H"'

Search Results

5. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation

7. Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery

8. High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer

9. Gynecologic oncology patient perspectives and knowledge on advance care planning: A quality improvement intervention

10. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography

11. Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care

12. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

14. Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial

15. Uterine carcinosarcomas: From pathology to practice

16. A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy

17. Impact of employment and insurance status on distress in gynecologic oncology patients

18. Obese endometrial cancer survivors’ perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventions

19. The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer

20. State of the science: Uterine sarcomas: From pathology to practice

21. A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education

22. Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?

23. FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival

26. Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention

28. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer

29. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression

30. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients

33. Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use

34. Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?

35. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study

36. Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?

37. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer

38. Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer

41. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study

42. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth

44. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

49. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study

50. Reply

Catalog

Books, media, physical & digital resources